Neil Gibson

Dr. Gibson, PhD, is an experienced drug developer, having contributed to the successful approval of multiple blockbuster oncology therapeutics, including temozolomide, erlotinib, crizotinib, and sorafenib. Dr. Gibson is currently the CEO of Adanate, an immunotherapy company. Previously, Dr. Gibson has held Chief Scientific Officer roles in multiple pharma and biotech companies, including Regulus Therapeutics, Pfizer Oncology, and OSI Pharmaceuticals. At Pfizer he was a member of the global R&D leadership team as well as a member of the Oncology Business unit leadership team. He has also held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. Dr. Gibson earned his PhD from the University of Aston, Birmingham, England.